RIMKLA Inhibitors
RIMKLA inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of RIMKLA, a member of the RimK family of proteins involved in post-translational modification. RIMKLA is an ATP-dependent ligase that plays a crucial role in modifying proteins by adding glutamate residues to the C-terminus of certain substrates, a process known as polyglutamylation. This modification affects the structural and functional properties of proteins, influencing their stability, activity, and interaction with other cellular components. By inhibiting RIMKLA, these compounds disrupt its ability to catalyze the addition of glutamate residues, potentially altering protein function and affecting downstream cellular processes that rely on precise post-translational modifications.
The design of RIMKLA inhibitors focuses on targeting the ATP-binding site or the active site of the enzyme, which is critical for its ligase activity. Inhibitors are often developed to compete with ATP or bind to other regions of the enzyme that are essential for its catalytic function. Structural biology techniques, such as X-ray crystallography and molecular docking, are used to map the active site of RIMKLA and to design compounds that can specifically bind and inhibit its activity. Specificity is a key consideration in developing RIMKLA inhibitors, as this enzyme shares structural similarities with other members of the RimK family and related ligases. By selectively targeting RIMKLA, researchers can study its specific role in protein modification and explore the broader impact of polyglutamylation on cellular function, protein interactions, and the regulation of critical biological processes. These inhibitors provide a valuable tool for understanding the mechanisms of protein modification and the functional consequences of interfering with such post-translational changes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is responsible for protein synthesis and cell growth. Inhibition of mTOR can lead to reduced protein synthesis, thus functionally inhibiting Ribosomal protein S6 modification-like protein A by preventing its potential overexpression and activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream of the mTOR pathway. By inhibiting PI3K, LY 294002 reduces activation of the mTOR pathway, thereby decreasing protein synthesis rates, which can functionally inhibit Ribosomal protein S6 modification-like protein A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, which blocks the PI3K/Akt/mTOR signaling pathway. This inhibition leads to decreased protein synthesis, which can result in functional inhibition of Ribosomal protein S6 modification-like protein A. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective inhibitor of mTOR kinase activity. By inhibiting mTOR, PP242 directly reduces the phosphorylation of S6 kinase, which in turn diminishes the activity of ribosomal protein S6, thus functionally inhibiting Ribosomal protein S6 modification-like protein A. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is an mTOR inhibitor that works across both mTORC1 and mTORC2 complexes. By broadly inhibiting mTOR function, Torin 1 leads to a reduction in protein synthesis, functionally inhibiting Ribosomal protein S6 modification-like protein A by hampering its modification processes. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
BEZ235 is a dual PI3K/mTOR inhibitor that leads to robust attenuation of the PI3K/Akt/mTOR signaling cascade. The reduced signaling through this pathway results in lower levels of protein synthesis and functional inhibition of Ribosomal protein S6 modification-like protein A. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent inhibitor of both mTORC1 and mTORC2 complexes. Its inhibition of mTOR activity results in decreased phosphorylation and activity of S6 kinase, thereby functionally inhibiting Ribosomal protein S6 modification-like protein A by limiting its modification capacity. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) inhibits the Akt/mTOR pathway, which results in decreased activity of downstream proteins like S6 kinase. The reduced activity of this kinase leads to the functional inhibition of Ribosomal protein S6 modification-like protein A by constraining its phosphorylation and activation. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU 0063794 directly inhibits mTORC1 and mTORC2 complexes, leading to a decrease in the phosphorylation of downstream targets such as S6 kinase, which in turn functionally inhibits Ribosomal protein S6 modification-like protein A by restricting its phosphorylation and subsequent activity. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is a derivative of rapamycin that similarly inhibits mTOR by binding to its intracellular receptor FKBP12. The formation of this complex inhibits mTORC1, which leads to a decrease in protein synthesis and functional inhibition of Ribosomal protein S6 modification-like protein A. | ||||||